A detailed history of Wolverine Trading, LLC transactions in Iovance Biotherapeutics, Inc. stock. As of the latest transaction made, Wolverine Trading, LLC holds 51,720 shares of IOVA stock, worth $387,382. This represents 0.0% of its overall portfolio holdings.

Number of Shares
51,720
Previous 33,995 52.14%
Holding current value
$387,382
Previous $272,000 78.31%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$7.28 - $11.9 $129,038 - $210,927
17,725 Added 52.14%
51,720 $485,000
Q2 2024

Aug 14, 2024

BUY
$7.78 - $14.19 $27,572 - $50,289
3,544 Added 11.64%
33,995 $272,000
Q1 2024

May 15, 2024

SELL
$7.59 - $17.47 $695,820 - $1.6 Million
-91,676 Reduced 75.07%
30,451 $451,000
Q4 2023

Feb 14, 2024

BUY
$3.3 - $8.89 $208,774 - $562,425
63,265 Added 107.48%
122,127 $992,000
Q3 2023

Nov 15, 2023

BUY
$4.44 - $8.79 $9,958 - $19,715
2,243 Added 3.96%
58,862 $267,000
Q2 2023

Aug 23, 2023

BUY
$5.36 - $9.06 $125,697 - $212,466
23,451 Added 70.7%
56,619 $398,000
Q1 2023

May 15, 2023

BUY
$5.53 - $8.22 $183,419 - $272,640
33,168 New
33,168 $204,000
Q3 2022

Nov 14, 2022

BUY
$9.53 - $13.11 $155,138 - $213,417
16,279 New
16,279 $155,000
Q1 2022

May 16, 2022

SELL
$12.38 - $19.1 $7,130 - $11,001
-576 Reduced 3.49%
15,912 $266,000
Q4 2021

Feb 14, 2022

SELL
$16.55 - $27.63 $128,610 - $214,712
-7,771 Reduced 32.03%
16,488 $320,000
Q3 2021

Nov 12, 2021

SELL
$20.35 - $26.63 $95,441 - $124,894
-4,690 Reduced 16.2%
24,259 $577,000
Q2 2021

Aug 06, 2021

BUY
$16.33 - $33.07 $472,737 - $957,343
28,949 New
28,949 $762,000

Others Institutions Holding IOVA

About IOVANCE BIOTHERAPEUTICS, INC.


  • Ticker IOVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 157,800,992
  • Market Cap $1.18B
  • Description
  • Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...
More about IOVA
Track This Portfolio

Track Wolverine Trading, LLC Portfolio

Follow Wolverine Trading, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wolverine Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Wolverine Trading, LLC with notifications on news.